experimental group Type of group

6 trials

Sponsors

MERCK SHARP & DOHME PERU S.R.L.,, SEGURO SOCIAL DE SALUD,, NOVARTIS BIOSCIENSES PERU S.A.,, MGI PHARMA, INC.,, INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP,

Early Phase 1

A PHASE II STUDY OF CHOP MAS RITUXIMAB WITH INTRATECAL METOTREXATE FOLLOWED BY RADIOTHERAPY IN PATIENTS WITH NON-HODGKIN PRIMARY LYMPHOMA TESTICULAR

Active, not recruitingPER-081-03

INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP,

Updated: 2023-09-04

Unknown Phase

EFFECT OF LOSARTAN COMPARED WITH CAPTOPRIL ON MORTALITY IN PATIENTS WITH SYMPTOMATIC HEART FAILURE: RANDOMISED TRIAL—THE LOSARTAN HEART FAILURE SURVIVAL STUDY ELITE II

MERCK SHARP & DOHME PERU S.R.L.,

Target: 110Updated: 2023-09-04

Multicenter, open-label study to evaluate the safety of Trlleptal® in patients with neuropathic pain due to diabetic neuropathy

Active, not recruitingPER-016-02

NOVARTIS BIOSCIENSES PERU S.A.,

Target: 31Updated: 2023-09-04

CLINICAL PHASE II STUDY OF IROFULVEN IN COMBINATION WITH IRINOTECAN IN PATIENTS WITH ADVANCED SOLID TUMORS GASTROINTESTINALES

Active, not recruitingPER-056-02

MGI PHARMA, INC.,

Updated: 2023-09-04

CONVALESCENT PLASMA AS TREATMENT FOR COVID-19

Active, not recruitingPER-013-20

SEGURO SOCIAL DE SALUD,

Start: 2020-06-01Target: 192Updated: 2023-09-04

A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF FUTIBATINIB VERSUS GEMCITABINE-CISPLATIN CHEMOTHERAPY AS FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED CHOLANGIOCARCINOMA HARBORING FGFR2 GENE REARRANGEMENTS (FOENIX-CCA3)

Active, not recruitingPER-098-20

Taiho Oncology, Inc.,

Start: 2021-04-01Target: 10Updated: 2023-11-13